IE922316A1 - Retroviral protease inhibitors - Google Patents
Retroviral protease inhibitorsInfo
- Publication number
- IE922316A1 IE922316A1 IE231692A IE922316A IE922316A1 IE 922316 A1 IE922316 A1 IE 922316A1 IE 231692 A IE231692 A IE 231692A IE 922316 A IE922316 A IE 922316A IE 922316 A1 IE922316 A1 IE 922316A1
- Authority
- IE
- Ireland
- Prior art keywords
- amino
- methyl
- phenyl
- isopropyl
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/68—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
- C07D233/95—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by nitrogen atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73156391A | 1991-07-17 | 1991-07-17 | |
US87097592A | 1992-04-20 | 1992-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
IE922316A1 true IE922316A1 (en) | 1993-01-27 |
Family
ID=27112266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE231692A IE922316A1 (en) | 1991-07-17 | 1992-07-16 | Retroviral protease inhibitors |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP0602069A4 (fr) |
JP (1) | JPH07500577A (fr) |
AP (1) | AP9200410A0 (fr) |
AU (1) | AU2412992A (fr) |
CA (1) | CA2113644A1 (fr) |
IE (1) | IE922316A1 (fr) |
IL (1) | IL102534A0 (fr) |
MX (1) | MX9204233A (fr) |
PT (1) | PT100704A (fr) |
WO (1) | WO1993002057A1 (fr) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6825169B1 (en) | 1991-10-22 | 2004-11-30 | Trustees Of Tufts College | Inhibitors of dipeptidyl-aminopeptidase type IV |
US6071895A (en) * | 1992-03-11 | 2000-06-06 | Narhex Limited | Polar-substituted hydrocarbons |
WO1993018006A1 (fr) * | 1992-03-11 | 1993-09-16 | Narhex Limited | Derives amines d'hydrocarbures a substitution oxo et hydroxy |
US5888992A (en) * | 1992-03-11 | 1999-03-30 | Narhex Limited | Polar substituted hydrocarbons |
DE69333270T2 (de) | 1992-03-11 | 2004-08-05 | Narhex Ltd. | Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen |
GB9207380D0 (en) * | 1992-04-03 | 1992-05-13 | Ici Plc | Compounds |
US5559256A (en) * | 1992-07-20 | 1996-09-24 | E. R. Squibb & Sons, Inc. | Aminediol protease inhibitors |
ES2068739B1 (es) * | 1993-01-21 | 1995-11-01 | Smithkline Beecham Corp | Inhibidores retrovirables de proteasas. |
IL110898A0 (en) * | 1993-09-10 | 1994-11-28 | Narhex Australia Pty Ltd | Polar-substituted hydrocarbons |
CA2179935C (fr) * | 1995-06-30 | 2010-09-07 | Ryohei Kato | Compose dipeptidique ou sel de ce dernier acceptable en pharmacie; utilisation en medecine |
US6222043B1 (en) | 1995-06-30 | 2001-04-24 | Japan Energy Corporation | Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof |
US5965532A (en) * | 1996-06-28 | 1999-10-12 | Trustees Of Tufts College | Multivalent compounds for crosslinking receptors and uses thereof |
CA2249747A1 (fr) | 1996-12-27 | 1998-07-09 | Tsutomu Mimoto | Nouveaux composes de tripeptides et medicaments anti-sida |
US6403587B1 (en) * | 1997-02-26 | 2002-06-11 | Pfizer Inc. | Heteroaryl-hexanoic acid amide derivatives, their preparation and their use as selective inhibitors of MIP-1-α binding to its CCR 1 receptor |
US6100234A (en) | 1997-05-07 | 2000-08-08 | Tufts University | Treatment of HIV |
US6040145A (en) | 1997-05-07 | 2000-03-21 | Tufts University | Potentiation of the immune response |
KR100458403B1 (ko) | 1997-09-29 | 2004-11-26 | 포인트 써러퓨틱스, 인크. | 생체외 조혈세포의 자극방법 |
EP1075266A1 (fr) | 1998-05-04 | 2001-02-14 | Point Therapeutics, Inc. | Stimulation hematopoietique |
PT1084129E (pt) | 1998-06-05 | 2003-06-30 | Point Therapeutics Inc | Compostos de boroprolina ciclica |
US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
EP1666452A2 (fr) | 2000-06-30 | 2006-06-07 | Elan Pharmaceuticals, Inc. | Composés pour le traitement de la maladie d'Alzheimer |
UY30805A1 (es) * | 2006-12-21 | 2008-07-31 | Bayer Schering Pharma Ag | Moduladores no esteroides de receptores de progesterona |
SG11202101486RA (en) | 2018-08-16 | 2021-03-30 | Innate Tumor Immunity Inc | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
US11851422B2 (en) | 2021-07-09 | 2023-12-26 | Aligos Therapeutics, Inc. | Anti-viral compounds |
CN114605320B (zh) * | 2022-04-06 | 2023-12-29 | 南京艾康生物科技有限公司 | 一种5-硝基-6-甲基烟酸乙酯的合成方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4431653A (en) * | 1982-03-18 | 1984-02-14 | Hoffmann-La Roche Inc. | Penicillanic acid derivatives |
IE20010533A1 (en) * | 1990-11-20 | 2003-03-05 | Abbott Lab | Intermediates for preparing retroviral protease inhibiting compounds |
-
1992
- 1992-07-16 IE IE231692A patent/IE922316A1/en not_active Application Discontinuation
- 1992-07-17 EP EP92917238A patent/EP0602069A4/fr not_active Withdrawn
- 1992-07-17 JP JP5503016A patent/JPH07500577A/ja active Pending
- 1992-07-17 IL IL102534A patent/IL102534A0/xx unknown
- 1992-07-17 MX MX9204233A patent/MX9204233A/es unknown
- 1992-07-17 WO PCT/US1992/006047 patent/WO1993002057A1/fr not_active Application Discontinuation
- 1992-07-17 PT PT100704A patent/PT100704A/pt not_active Application Discontinuation
- 1992-07-17 AP APAP/P/1992/000410A patent/AP9200410A0/en unknown
- 1992-07-17 CA CA002113644A patent/CA2113644A1/fr not_active Abandoned
- 1992-07-17 AU AU24129/92A patent/AU2412992A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AP9200410A0 (en) | 1992-07-31 |
PT100704A (pt) | 1993-10-29 |
AU2412992A (en) | 1993-02-23 |
IL102534A0 (en) | 1993-01-14 |
JPH07500577A (ja) | 1995-01-19 |
EP0602069A4 (fr) | 1995-05-03 |
MX9204233A (es) | 1994-06-30 |
EP0602069A1 (fr) | 1994-06-22 |
CA2113644A1 (fr) | 1993-02-04 |
WO1993002057A1 (fr) | 1993-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IE922316A1 (en) | Retroviral protease inhibitors | |
US5733882A (en) | Retroviral protease inhibitors | |
KR100336699B1 (ko) | 레트로바이러스 프로테아제 저해제로서 유용한히드록시에틸아미노 술폰아미드 | |
DE69635183T2 (de) | Verbindungen der Struktur Bis-Aminosäurehydroxyethylaminosulfonamid als Inhibitoren der retroviralen Protease | |
JP4014220B2 (ja) | ビス−スルホンアミドヒドロキシエチルアミノ レトロ ウイルスプロテアーゼインヒビター | |
DE69311810T2 (de) | N-(alkanoylamino-2-hydroxypropyl)-sulfonamide verwendbar als retrovirale proteaseninhibitoren | |
EP0415981A1 (fr) | Inhibiteurs de protease retrovirale | |
EP0337714A3 (fr) | Inhibiteurs de la protéase du HIV pour le traitement du SIDA | |
EP0412350A2 (fr) | Inhibiteurs de la rénine, procedure de leur préparation de leur utilisation comme médicament | |
MXPA06006609A (es) | Compuestos inhibidores de proteasa de vih. | |
EP0538396A1 (fr) | Inhibiteurs de proteases retrovirales | |
WO2000059867A1 (fr) | Derives d'hydroxyphenyle possedant des proprietes inhibitrices de l'integrase du vih | |
JPH10512571A (ja) | レトロウイルスプロテアーゼインヒビター中間体の製造方法 | |
EP0538383A1 (fr) | Inhibiteurs de proteases aspartiques | |
EP0603309A1 (fr) | Isosteres peptidiques contenant un heterocycle utilises comme inhibiteurs du v.i.h. | |
WO1993017003A1 (fr) | Inhibiteurs de la protease retrovirale | |
US20050009890A1 (en) | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | |
US12030856B2 (en) | Potassium channel inhibitors | |
WO2023174836A1 (fr) | Dérivés d'imidazole utilisés en tant qu'inhibiteurs des canaux potassiques | |
RU2173680C2 (ru) | Гидроксиэтиламиносульфонамиды, промежуточные соединения, фармацевтическая композиция, способ ингибирования ретровирусных протеаз, способ лечения ретровирусных инфекций, способ лечения спида | |
CA2267657A1 (fr) | Derives hydroxyphenyliques ayant des proprietes inhibitrices de vih-integrase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC9A | Application refused sect. 31(1) |